JP6170040B2 - ピルフェニドン及び選択された患者における抗線維化療法 - Google Patents

ピルフェニドン及び選択された患者における抗線維化療法 Download PDF

Info

Publication number
JP6170040B2
JP6170040B2 JP2014512134A JP2014512134A JP6170040B2 JP 6170040 B2 JP6170040 B2 JP 6170040B2 JP 2014512134 A JP2014512134 A JP 2014512134A JP 2014512134 A JP2014512134 A JP 2014512134A JP 6170040 B2 JP6170040 B2 JP 6170040B2
Authority
JP
Japan
Prior art keywords
pirfenidone
fvc
receptor
inhibitors
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014512134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518880A (ja
JP2014518880A5 (cg-RX-API-DMAC7.html
Inventor
ウイリアムソン ジーグラー ブラッドフォード,
ウイリアムソン ジーグラー ブラッドフォード,
Original Assignee
インターミューン, インコーポレイテッド
インターミューン, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターミューン, インコーポレイテッド, インターミューン, インコーポレイテッド filed Critical インターミューン, インコーポレイテッド
Publication of JP2014518880A publication Critical patent/JP2014518880A/ja
Publication of JP2014518880A5 publication Critical patent/JP2014518880A5/ja
Application granted granted Critical
Publication of JP6170040B2 publication Critical patent/JP6170040B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014512134A 2011-05-25 2012-05-25 ピルフェニドン及び選択された患者における抗線維化療法 Expired - Fee Related JP6170040B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161489936P 2011-05-25 2011-05-25
US61/489,936 2011-05-25
US201161490057P 2011-05-26 2011-05-26
US61/490,057 2011-05-26
US201161523047P 2011-08-12 2011-08-12
US61/523,047 2011-08-12
US201161524961P 2011-08-18 2011-08-18
US61/524,961 2011-08-18
PCT/US2012/039538 WO2012162592A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Publications (3)

Publication Number Publication Date
JP2014518880A JP2014518880A (ja) 2014-08-07
JP2014518880A5 JP2014518880A5 (cg-RX-API-DMAC7.html) 2015-07-02
JP6170040B2 true JP6170040B2 (ja) 2017-07-26

Family

ID=47217770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512134A Expired - Fee Related JP6170040B2 (ja) 2011-05-25 2012-05-25 ピルフェニドン及び選択された患者における抗線維化療法

Country Status (11)

Country Link
US (1) US20150164874A1 (cg-RX-API-DMAC7.html)
EP (1) EP2713732A4 (cg-RX-API-DMAC7.html)
JP (1) JP6170040B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140022048A (cg-RX-API-DMAC7.html)
AU (1) AU2012258575B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835438A1 (cg-RX-API-DMAC7.html)
HK (1) HK1197159A1 (cg-RX-API-DMAC7.html)
IL (1) IL229226A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013013752A (cg-RX-API-DMAC7.html)
SG (1) SG195110A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012162592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
BR112013022766A2 (pt) * 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP3194446B1 (en) * 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
DK3050574T3 (da) * 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US20210363259A1 (en) * 2017-08-22 2021-11-25 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
CA3140129A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Mps modified peptides and use thereof
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁(杭州)生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN114617890A (zh) * 2020-12-08 2022-06-14 四川夏派森医药科技有限公司 DH404在治疗SARS-CoV-2感染中的应用
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
CN1307997C (zh) * 2002-06-28 2007-04-04 图兰恩教育基金管理人 用于治疗肺纤维化的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-(吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺
WO2004103296A2 (en) * 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
HUE052220T2 (hu) * 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
NZ617415A (en) 2017-07-28
US20150164874A1 (en) 2015-06-18
EP2713732A1 (en) 2014-04-09
WO2012162592A1 (en) 2012-11-29
JP2014518880A (ja) 2014-08-07
KR20140022048A (ko) 2014-02-21
HK1197159A1 (en) 2015-01-09
SG195110A1 (en) 2013-12-30
CA2835438A1 (en) 2012-11-29
EP2713732A4 (en) 2014-12-03
AU2012258575A1 (en) 2013-11-21
AU2012258575B2 (en) 2017-03-02
IL229226A0 (en) 2014-01-30
MX2013013752A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
JP2014518880A (ja) ピルフェニドン及び選択された患者における抗線維化療法
JP2014518880A5 (cg-RX-API-DMAC7.html)
JP6532878B2 (ja) 組合せ医薬
KR102293847B1 (ko) 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도
US9216170B2 (en) Combination therapy for proliferative disorders
Patel et al. Macitentan: first global approval
US20120128665A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
JP2015028062A (ja) 糖尿病の合併症のための療法
JP2017538701A (ja) サルコペニアの治療のためのミオスタチンまたはアクチビンアンタゴニスト
TWI857060B (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
JP2014503500A (ja) 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
JP2020513005A (ja) Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
JP2023546536A (ja) 線維症を処置する方法
JP2012526772A (ja) ホスホイノシチド3−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
TW202615042A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
WO2019053595A1 (en) INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA
US11508483B2 (en) Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
Kanesvaran et al. A single-arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma
TWI656876B (zh) 治療pah之抗增生劑
JP2007519646A (ja) 体重の持続的低減のための化合物
JP2022548214A (ja) ビルダグリプチンとメトホルミンとの組み合わせ療法
NZ617415B2 (en) Pirfenidone and anti-fibrotic therapy in selected patients
WO2005048999A2 (en) Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders
US20160022654A1 (en) Methods of Improving Microvascular Integrity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170629

R150 Certificate of patent or registration of utility model

Ref document number: 6170040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees